Induced pluripotent stem cell

Creative Medical Technology Holdings Provides Corporate Update

Retrieved on: 
Wednesday, November 15, 2023
Safety, Induced pluripotent stem cell, IRB, Gynaecology, Radiation, Security (finance), ODD, Endocrinology, Share repurchase, Clinical trial, Urology, Elective surgery, IPSC, Consultant, Patient, FDA, Type 1 diabetes, Stanford University, Therapy, Cell bank, Immortalised cell line, Pain, Phase, Type 2 diabetes, Type 2, Form 10-Q, Immunotherapy, Drug Master File, Pharmaceutical industry, Medical device, Vaccine

PHOENIX, Nov. 15, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided an update on recent business activities in connection with the filing of its Form 10-Q with the Securities and Exchange Commission.  

Key Points: 
  • PHOENIX, Nov. 15, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided an update on recent business activities in connection with the filing of its Form 10-Q with the Securities and Exchange Commission.
  • "We continue to make progress developing our regenerative therapeutics, building important assets, and managing a robust product pipeline, while maintaining a strong financial position," said Timothy Warbington, Chief Executive Officer of Creative Medical Technology.
  • "Our work is supported by a strong intellectual property portfolio consisting of more than 68 patents and patents pending.
  • For the three months ended September 30, 2023 the Company repurchased 40,000 shares of its common stock under the Repurchase Plan.

Global Stem Cell Market Report 2021: Forecast to 2025 & 2030 Featuring Anterogen, Mesoblast, Osiris Therapeutics, AlloSource, and Cellular Engineering Technologies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 1, 2022
Biotechnology, Health, Science, Stem Cells, Research, Growth, Stem, Center for Biologics Evaluation and Research, Patient, Food and Drug Administration, Cell, Immune system, Food, Diabetes, Cancer, Physician, Center, Bone marrow, Tissue, Embryonic, Stem cell, Environment, Transplant, IPSC, Woman, Efficiency, COVID-19, Chronic condition, Induced pluripotent stem cell, Adult, Degenerative disease, Disease, Prevalence, Gene, Drug discovery, Health, Neurodegeneration, Blood, Potency (pharmacology), Induce, FDA, Therapy, Presidential Commission for the Study of Bioethical Issues, B cell, Vaccine, Pharmaceutical industry, Medical device, Research

Major players in the stem cell market are Anterogen Co. Ltd, Mesoblast Ltd, Osiris Therapeutics Inc, AlloSource, and Cellular Engineering Technologies.

Key Points: 
  • Major players in the stem cell market are Anterogen Co. Ltd, Mesoblast Ltd, Osiris Therapeutics Inc, AlloSource, and Cellular Engineering Technologies.
  • The stem cell market consists of sales of stem cells products such as human embryonic stem cell, induced pluripotent stem cell and adult stem cell.
  • The low acceptance rate for stem cell therapy treatments is restraining the growth of the stem cell market.
  • Companies in the stem cell therapeutics market are focusing on development of new technologies such as the Induced Pluripotent Stem Cells (IPSC) to boost the efficiency of stem cell therapies.

Cellino Appoints Industry Pioneer Robert J. Palay to the Board

Retrieved on: 
Tuesday, August 3, 2021
Technology, Surgery, Medical devices, General Health, Science, Genetics, Biotechnology, Health, Other Science, Research, Other Technology, Software, Other Health, Hardware, Pharmaceutical, Stem cells, Oncology, Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Cloning, Developmental biology, Induced pluripotent stem cell, Cellino, IPSC

Cellino , a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the appointment of industry pioneer Robert J. Palay, J.D., M.B.A., to the Cellino Board of Directors.

Key Points: 
  • Cellino , a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the appointment of industry pioneer Robert J. Palay, J.D., M.B.A., to the Cellino Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20210803005032/en/
    Mr. Palay is one of the pioneers of the induced pluripotent stem cell (iPSC) industry.
  • "We are pleased to welcome Robert to the Cellino Board," said Nabiha Saklayen, Ph.D, CEO & Co-Founder, Cellino.
  • "I am thrilled to join the Cellino Board," said Robert J. Palay.

City of Hope Researchers Develop Miniature Brain Models to Study the Causes of Alzheimer’s Disease and to Test Drugs in Development

Retrieved on: 
Monday, August 2, 2021
Oncology, Health, Hospitals, Other Health, Other Science, Research, Science, Branches of biology, Biology, Stem cells, Life sciences, Organoid, Cerebral organoid, Induced pluripotent stem cell

We, at City of Hope, have created a miniature brain model that uses human stem cell technology to study Alzheimers disease and, hopefully, to help find treatments for this devastating illness.

Key Points: 
  • We, at City of Hope, have created a miniature brain model that uses human stem cell technology to study Alzheimers disease and, hopefully, to help find treatments for this devastating illness.
  • City of Hope researchers were able to model sporadic Alzheimers disease, the most common form of the condition, using brain organoids derived using human induced pluripotent stem cell (hiPSC) technology.
  • Because Alzheimers is a disease of age, the scientists exposed the models to serum to mimic age-associated blood-brain barrier breakdown.
  • Huentelman is a leading expert in the genetic study of Alzheimers disease and was not part of this study.

Quell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, T cells, Stem cells, Regulatory T cell, IPSCS, Induced pluripotent stem cell

LONDON and BOSTON, July 29, 2021 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer.

Key Points: 
  • LONDON and BOSTON, July 29, 2021 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer.
  • "We are delighted to welcome Tracey to Quell.
  • She brings impressive drug discovery experience working with a wide range of cell therapy platforms, including induced pluripotent stem cells (iPSCs), Treg and T-effector cells and genetic engineering," said Iain McGill, Chief Executive Officer of Quell Therapeutics.
  • "We believe that Tracey's extensive technical and therapeutic expertise enhances our industry leading engineered Treg cell therapy development capabilities and reinforces our proven operational competency.

Quell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, Stem cells, T cells, IPSCS, Regulatory T cell, Induced pluripotent stem cell

LONDON and BOSTON, July 29, 2021 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer. Dr. Lodie brings to Quell more than 20 years of experience in the biopharmaceutical industry focused on the discovery and development of cell therapies and novel biologics in the areas of autoimmunity, transplant biology and immune-oncology.

Key Points: 
  • "We are delighted to welcome Tracey to Quell.
  • She brings impressive drug discovery experience working with a wide range of cell therapy platforms, including induced pluripotent stem cells (iPSCs), Treg and T-effector cells and genetic engineering," said Iain McGill, Chief Executive Officer of Quell Therapeutics.
  • "We believe that Tracey's extensive technical and therapeutic expertise enhances our industry leading engineered Treg cell therapy development capabilities and reinforces our proven operational competency.
  • Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases.

Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma

Retrieved on: 
Friday, July 16, 2021
Life sciences, Biology, Biotechnology, Induced stem cells, Developmental biology, Stem cells, IPSCS, Biopharmaceutical, Cellular differentiation, Induced pluripotent stem cell

The archived webcast will be available on the Company's website beginning approximately two hours after the event.

Key Points: 
  • The archived webcast will be available on the Company's website beginning approximately two hours after the event.
  • Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body.
  • Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.

Vyant Bio Announces Issuance of Key Patent for High-Throughput Optical Assay of Human Mixed Cell Population Spheroids

Retrieved on: 
Tuesday, July 13, 2021
Life sciences, Natural sciences, Intellectual property law, Biotechnology, Stem cells, Assay, Biochemistry, Titration, United States Patent and Trademark Office, Patent, Drug discovery, Induced pluripotent stem cell

11054408, titled High Throughput Optical Assay of Human Mixed Cell Population Spheroids by the United States Patent and Trademark Office (USPTO).

Key Points: 
  • 11054408, titled High Throughput Optical Assay of Human Mixed Cell Population Spheroids by the United States Patent and Trademark Office (USPTO).
  • The issuance of the 11054408 patent is the third patent granted to StemoniX: additional applications are currently pending worldwide.
  • Human iPSCs offer many advantages over recombinant cell lines or primary rodent cells for use in drug screening.
  • Vyant Bio, Inc. (Vyant Bio, the Company) (Nasdaq: VYNT) is emerging as an advanced biotechnology drug discovery company.

Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates

Retrieved on: 
Saturday, June 26, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Cell biology, Developmental biology, Induced pluripotent stem cell, IPSCS, Immunosuppression

SEATTLE, June 26, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today presented data showing survival of transplanted stem cells without immunosuppression in non-human primates (NHPs).

Key Points: 
  • SEATTLE, June 26, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today presented data showing survival of transplanted stem cells without immunosuppression in non-human primates (NHPs).
  • The transplanted cells were induced pluripotent stem cells (iPSCs) with Sanas hypoimmune gene modifications that enable immune evasion.
  • Sanas hypoimmune (HIP) platforms goal is to eliminate the need for immunosuppression by cloaking cells from immune recognition.
  • Sana Biotechnology and the Sana Biotechnology logo are trademarks of Sana Biotechnology, Inc. or its subsidiaries.

Alphageneron to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th, 2021

Retrieved on: 
Saturday, June 26, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cell biology, Induced stem cells, Immune system, Natural killer cell, Induced pluripotent stem cell, Cell therapy, IPSCS

CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (Alphageneronor theCompany), a privately-held clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer (NK) cellular and antibody therapeutics announced that Robert Brooks, JD, founder and Chief Executive Officer of Alphageneron, will participate in the ROTH Healthcare Private Company Forum to be hosted virtually on Monday, June 28, 2021.

Key Points: 
  • CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (Alphageneronor theCompany), a privately-held clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer (NK) cellular and antibody therapeutics announced that Robert Brooks, JD, founder and Chief Executive Officer of Alphageneron, will participate in the ROTH Healthcare Private Company Forum to be hosted virtually on Monday, June 28, 2021.
  • Alphageneron is also planning a Phase I clinical Combination trial with Metastatic Colorectal cancer withallogeneic donor genetically edited NK cell therapy, (ANKASTIM) in the United States.
  • To register for this virtual event click www.roth.com/healthcareprivateday or please contact Gerald Roger, c/o Trinity Capital Advisers Tel.
  • Alphageneron is also developing allogeneic Induced pluripotent stem cells (iPSCs) CAR-engineered NK (CAR NK) cells to an undisclosed target.